CASP1 and COVID-19: Potential drug candidates for such an intervention include Tadekinig Alfa (AB2Bio), a recombinant human interleukin-18 binding protein, having shown efficacy in conditions with elevated fIL-18, such as MAS [50] and sJIA [30], and caspase-1 inhibitor, Belnacasan (Roivant), currently in Phase 2 trials for COVID-19 [51], having shown efficacy in reducing pulmonary inflammation in animal models [52].